Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GH | Guardant Health, Inc. | 2025-10-30 19:48:29 | 92.69 | 0.28 | 0.3 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GH | 0001576280 | Guardant Health, Inc. | US40131M1099 | 254900M8C3E5VC8BR186 | 454139254 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 3100 HANOVER STREET | PALO ALTO | CA | 94304 | UNITED STATES | US | 855-698-8887 | 3100 HANOVER STREET, PALO ALTO, CA, 94304 | 3100 HANOVER STREET, PALO ALTO, CA, 94304 | — | Biotechnology | 2012 | Helmy Eltoukhy | 1,400 | http://guardanthealth.com | 3,400,000,000 | 125,982,066 | 126,041,089 | Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers. | 2025-10-30 13:06:59 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 3,400,000,000 | -700,000,000 | -17.0732 | 123,421,441 | 1,708,717 | 1.4039 |
| 2023 | 4,100,000,000 | 100,000,000 | 2.5 | 121,712,724 | 19,048,990 | 18.5547 |
| 2022 | 4,000,000,000 | -8,100,000,000 | -66.9421 | 102,663,734 | 797,896 | 0.7833 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Darya Chudova | Chief Technology Officer | 2023 | 424,462 | 0 | 2,222,397 | 279,281 | 11,919 | 4,755,541 |
| Helmy Eltoukhy | Co-Chief Executive Officer, Chairman | 2023 | 1 | 0 | 0 | 0 | 11,590 | 11,591 |
| Amirali Talasaz | Co-Chief Executive Officer | 2023 | 1 | 0 | 0 | 0 | 26,414 | 26,415 |
| Michael Bell | Chief Financial Officer | 2023 | 482,000 | 0 | 1,851,413 | 327,375 | 9,900 | 4,123,993 |
| Craig Eagle | Chief Medical Officer | 2023 | 497,462 | 0 | 1,565,107 | 337,500 | 9,900 | 3,485,356 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 2,021 |
| 2023 | 1,779 |
| 2022 | 1,793 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 739,016,000 | 563,948,000 | 449,538,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 347,753,000 | 367,194,000 | 373,807,000 |
| General And Administrative Expenses | 180,123,000 | 155,800,000 | 163,956,000 |
| Operating Expenses | 1,182,610,000 | 1,128,673,000 | 993,916,000 |
| Operating Income | -443,594,000 | -564,725,000 | -544,378,000 |
| Net Income | -436,373,000 | -479,449,000 | -654,588,000 |
| Earnings Per Share Basic | -3.56 | -4.28 | -6.41 |
| Earnings Per Share Diluted | -3.56 | -4.28 | -6.41 |
| Weighted Average Shares Outstanding Basic | 122,745,000 | 111,988,000 | 102,178,000 |
| Weighted Average Shares Outstanding Diluted | 122,745,000 | 111,988,000 | 102,178,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 525,540,000 | 1,133,537,000 | 141,647,000 |
| Marketable Securities Current | 314,438,000 | 35,097,000 | 869,584,000 |
| Accounts Receivable | 110,253,000 | 88,783,000 | 97,256,000 |
| Inventories | 71,083,000 | 61,948,000 | 51,598,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,055,114,000 | 1,347,106,000 | 1,191,594,000 |
| Marketable Securities Non Current | — | 98,002,000 | 0 |
| Property Plant And Equipment | 136,813,000 | 145,096,000 | 167,920,000 |
| Other Assets Non Current | 37,152,000 | 124,334,000 | 61,453,000 |
| Total Assets Non Current | 430,495,000 | 439,315,000 | 418,391,000 |
| Total Assets | 1,485,609,000 | 1,786,421,000 | 1,609,985,000 |
| Accounts Payable | 38,551,000 | 51,741,000 | 68,911,000 |
| Deferred Revenue | 35,468,000 | 17,965,000 | 17,403,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | — | 187,952,000 | — |
| Total Liabilities Current | 225,583,000 | 205,917,000 | 193,220,000 |
| Long Term Debt | 1,142,547,000 | 1,139,966,000 | 1,137,391,000 |
| Other Liabilities Non Current | 92,834,000 | 96,006,000 | 9,179,000 |
| Total Liabilities Non Current | 1,399,673,000 | 1,421,820,000 | 1,356,585,000 |
| Total Liabilities | 1,625,256,000 | 1,627,737,000 | 1,549,805,000 |
| Common Stock | 1,000 | 1,000 | 1,000 |
| Retained Earnings | -2,578,235,000 | -2,141,862,000 | -1,662,413,000 |
| Accumulated Other Comprehensive Income | -5,201,000 | -3,675,000 | -19,522,000 |
| Total Shareholders Equity | -139,647,000 | 158,684,000 | 60,180,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 42,387,000 | 42,881,000 | 35,962,000 |
| Share Based Compensation Expense | 140,411,000 | 90,759,000 | 94,685,000 |
| Other Non Cash Income Expense | -2,228,000 | 1,182,000 | -21,000 |
| Change In Accounts Receivable | 21,389,000 | -8,378,000 | -375,000 |
| Change In Inventories | 9,135,000 | 10,350,000 | 20,926,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 2,375,000 | -1,298,000 | -11,698,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -239,858,000 | -324,975,000 | -309,463,000 |
| Purchases Of Marketable Securities | 307,323,000 | 629,902,000 | 303,757,000 |
| Sales Of Marketable Securities | 35,000,000 | 1,494,700,000 | 555,000,000 |
| Acquisition Of Property Plant And Equipment | 35,085,000 | 20,486,000 | 77,461,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | -1,531,000 | — |
| Cash From Investing Activities | -261,308,000 | 840,250,000 | 149,816,000 |
| Tax Withholding For Share Based Compensation | 15,681,000 | 11,197,000 | 7,878,000 |
| Payments Of Dividends | 0 | 0 | 0 |
| Issuance Of Common Stock | 0 | 493,116,000 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -153,000 | 6,028,000 | — |
| Cash From Financing Activities | -996,000 | 477,375,000 | -189,093,000 |
| Change In Cash | -503,932,000 | 991,739,000 | -350,340,000 |
| Cash At End Of Period | 525,540,000 | 1,133,537,000 | 141,647,000 |
| Income Taxes Paid | 1,007,000 | 1,969,000 | 1,331,000 |
| Interest Paid | — | 2,578,000 | 2,577,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -3.56 | -4.28 | -6.41 |
| Price To Earnings Ratio | -8.5815 | -6.3201 | -4.2434 |
| Earnings Growth Rate | -16.8224 | -33.2293 | 60.25 |
| Price Earnings To Growth Ratio | 0.5101 | 0.1902 | -0.0704 |
| Book Value Per Share | -1.1377 | 1.417 | 0.589 |
| Price To Book Ratio | -26.8524 | 19.09 | 46.1821 |
| Ebitda | -390,398,000 | -432,021,000 | -614,718,000 |
| Enterprise Value | 4,366,866,750 | 3,035,704,400 | 3,774,985,600 |
| Dividend Yield | 0 | 0 | 0 |
| Dividend Payout Ratio | 0 | 0 | 0 |
| Debt To Equity Ratio | -8.1817 | 7.1839 | 18.8998 |
| Capital Expenditures | 34,104,000 | 20,057,000 | 79,421,000 |
| Free Cash Flow | -273,962,000 | -345,032,000 | -388,884,000 |
| Return On Equity | 3.1248 | -3.0214 | -10.8772 |
| One Year Beta | 1.5288 | 1.6823 | 2.2017 |
| Three Year Beta | 1.9869 | 1.9129 | 1.3177 |
| Five Year Beta | 1.3605 | 1.3788 | 1.3629 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| MIGNONE ROBERTO | Director | 2025-10-21 | 3,167 | A | 3,167 |
| MIGNONE ROBERTO | Director | 2025-10-21 | 3,167 | D | 9,504 |
| POTTER MYRTLE S | Director | 2025-10-17 | 26 | D | 18,324 |
| Tariq Musa | Director | 2025-10-17 | 116 | D | 7,725 |
| Hidalgo Medina Manuel | Director | 2025-10-17 | 232 | A | 1,315 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 2025-09-30 | 91,926,448 | 1,471,294 | 62.48 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 2025-09-30 | 912,459 | 14,604 | 62.4801 |
| Parkside Financial Bank & Trust | 2025-09-30 | 5,249 | 84 | 62.4881 |
| STRS OHIO | 2025-09-30 | 1,905,640 | 30,500 | 62.48 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 2025-09-30 | 34,739,442 | 556,009 | 62.48 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2025-08-31 | Global X Genomics & Biotechnology ETF | GNOM | 36,761 | 2,478,426.62 | 5.3797 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Multi-Asset Real Return Fund - Class A | SEIAX | 659 | 44,429.78 | 0.0059 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Small Cap II Fund - Class A | SECAX | 4,588 | 309,322.96 | 0.1269 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT SMALL CAP FUND - CLASS A | SLPAX | 2,226 | 150,076.92 | 0.0792 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Extended Market Index Fund - Class A | SMXAX | 17,800 | 1,200,076 | 0.099 |